Analyst Ratings For Ra Pharmaceuticals (NASDAQ:RARX)
Today, Credit Suisse Group lowered its price target on Ra Pharmaceuticals (NASDAQ:RARX) to $14.00 per share.
Some recent analyst ratings include
- 12/5/2017-Royal Bank of Canada Reiterated Rating of Buy.
- 9/28/2017-Jefferies Group Reiterated Rating of Buy.
- 11/21/2016-SunTrust Banks initiated coverage with a Buy rating.
Recent Insider Trading Activity For Ra Pharmaceuticals (NASDAQ:RARX)
Ra Pharmaceuticals (NASDAQ:RARX) has insider ownership of 14.50% and institutional ownership of 69.60%.
- On 6/19/2017 Bioventures Ltd Novartis, Major Shareholder, sold 56,420 with an average share price of $21.29 per share and the total transaction amounting to $1,201,181.80.
- On 6/7/2017 Bioventures Ltd Novartis, Major Shareholder, sold 12,114 with an average share price of $22.63 per share and the total transaction amounting to $274,139.82.
- On 6/5/2017 Bioventures Ltd Novartis, Major Shareholder, sold 19,647 with an average share price of $23.38 per share and the total transaction amounting to $459,346.86.
- On 6/1/2017 Bioventures Ltd Novartis, Major Shareholder, sold 46,261 with an average share price of $23.93 per share and the total transaction amounting to $1,107,025.73.
- On 5/26/2017 Bioventures Ltd Novartis, Major Shareholder, sold 5,353 with an average share price of $25.14 per share and the total transaction amounting to $134,574.42.
- On 5/24/2017 Bioventures Ltd Novartis, Major Shareholder, sold 17,451 with an average share price of $25.01 per share and the total transaction amounting to $436,449.51.
- On 5/18/2017 Bioventures Ltd Novartis, Major Shareholder, sold 9,019 with an average share price of $25.50 per share and the total transaction amounting to $229,984.50.
Recent Trading Activity for Ra Pharmaceuticals (NASDAQ:RARX)
Shares of Ra Pharmaceuticals closed the previous trading session at 6.46 up +0.06 0.94% with 6.389999866485596 shares trading hands.
